Disordered regulation of coagulation and platelet activation in xenotransplantation

Xenotransplantation

Volumn 7, Issue 3, 2000, Pages 166-176

  Robson, Simon C ^a   Cooper, David K C ^b   D'Apice, Anthony J F ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Coagulation; Endothelial cells; Molecular incompatibility; Platelets; Xenotransplantation

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR;

ARTICLE; BLOOD CLOTTING DISORDER; CELL ACTIVATION; COMPLEMENT INHIBITION; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; XENOGRAFT; XENOTRANSPLANTATION;

ANIMAL; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; GRAFT REJECTION; HUMAN; PLATELET ACTIVATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033806674     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2000.00067.x     Document Type: Article

References (100)

1. Modification of vascular responses in xenotransplantation - Inflammation and apoptosis
2. Delayed xenograft rejection
3. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors
4. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions
5. Loss of ATP diphosphohydrolase activity with endothelial cell activation
6. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts
7. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption
8. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons
9. Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection
10. Thrombin inhibition in discordant xenograft rejection
11. Inhibition of platelet integrin GpIIbIIIa prolongs survival of discordant cardiac xenografts
12. Inhibition of platelet GpIIbIIIa in an ex vivo model of hyperacute xenograft rejection does not prolong cardiac survival time
13. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts
14. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants
15. In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection
16. Apyrase administration prolongs discordant xenograft survival
17. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
18. Modulation of nucleoside triphosphate diphosphohydrolase-1/CD39 in xenograft rejection
19. Recombinant adenoviral mediated CD39 gene transfer prolongs cardiac xenograft survival
20. Relationship of platelets, blood coagulation, and fibrinolysis to hyperacute rejection of renal xenografts
21. Coagulation changes in hyperacute rejection of renal xenografts
22. Extracorporeal (ex vivo) connection of pig kidneys to humans 1. Clinical data and studies of platelet destruction
23. Immunopathology of porcine livers perfused with blood of humans with fulminant hepatic failure
24. Transgenic human decay accelerating factor makes normal pigs function as a concordant species
25. Endothelial cells from human decay acceleration factor transgenic pigs are protected against complement mediated tissue factor expression in vitro
26. Genetic engineering of pigs for xenogeneic heart transplantation
27. Characterization of pigs transgenic for human decay-accelerating factor
28. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors
29. Orthotopic heart transplantation in a transgenic pig-to-primate model
30. Overcoming rejection in pig-to-primate cardiac xenotransplantation
31. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts
32. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury
33. Transgenic pigs expressing human cd59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage
34. The emerging concept of vascular remodeling
35. Pharmacology of cyclophosphamide and metabolites
36. Apheresis and column absorption for specific removal of Gal-alpha-1, 3 Gal natural antibodies in a pig-to-baboon model
37. Coagulation and thrombotic disorders associated with pig organ and hemopoietic cell transplantation in non-human primates
38. Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection
39. Shwartzman reaction after human renal homotransplantation
40. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
41. Transient perturbation of endothelial integrity induced by natural antibodies and complement
42. Complement-mediated regulation of tissue factor activity in endothelium
43. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells - Type II activation
44. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells - Type I activation
45. Tyrosine phosphorylation following lectin mediated endothelial cell stimulation
46. The importance of nonimmune factors in reconstitution by discordant xenogeneic hematopoietic cells
47. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys
48. Tolerance to discordant xenografts. 1. Sharing of human natural antibody determinants on miniature swine bone marrow cells and endothelial cells
49. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura
50. Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S
51. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
52. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura hemolytic uremic syndrome following bone marrow transplantation
53. Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation - A case of hemolytic uremic syndrome
54. Thrombotic thrombocytopenic purpura - A rare late complication of allogeneic bone marrow transplantation
55. Role of endothelial cells in transplantation
56. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection
57. Disordered thromboregulation in discordant xenograft rejection
58. Molecular barriers to xenotransplantation
59. Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells
60. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein c by human mononuclear phagocytes
61. Xenogeneic endothelial cells activate human prothrombin
62. Endothelial cell activation and thromboregulation during xenograft rejection
63. The evaluation of thrombomodulin activity in porcine to human xenotransplantation
64. Activation of human prothrombin by porcine aortic endothelial cells - A potential barrier to pig to human xenotransplantation
65. Inhibitory mechanism of the protein c pathway on tissue factor-induced thrombin generation - Synergistic effect in combination with tissue factor pathway inhibitor
66. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II
67. Factors in xenograft rejection
68. Thrombin activates nuclear factor-kappa-b and potentiates endothelial cell activation by TNF
69. Aggregation of human platelets induced by porcine endothelial cells is dependent upon both activation of complement and thrombin generation
70. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
71. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein c
72. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
73. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi
74. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop
75. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1
76. Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation
77. Platelets in xenograft rejection
78. Platelet activation by C1q results in the induction of aII/bIII integrins and the expression of P-selectin and procoagulant activity
79. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay
80. Activation of human platelets by the membrane-expressed al domain of von-Willebrand-factor
81. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex
82. Porcine von Willebrand factor binding to human platelet GpIb induces transmembrane calcium influx
83. Identification and characterization of CD39 vascular ATP diphosphohydrolase
84. Extracellular ATP and ADP activate transcription factor NF-kappa-b and induce endothelial cell apoptosis
85. The procoagulant response of cytomegalovirus infected endothelial cells
86. Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection
87. Structurally homologous ligand binding of integrin mac-1 and viral glycoprotein-C receptors
88. Von Willebrand factor mediates platelet adhesion to virally infected endothelial cells
89. Identification of a monocyte receptor on herpesvirus-infected endothelial cells
90. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody
91. Infectious concerns of cross-species transplantation - Xenozoonoses
92. Xenotransplantation and xenogeneic infections
93. Transgenic expression of a CD46 (membrane cofactor protein) minigene - Studies of xenotransplantation and measles virus infection
94. Measles virus induction of human endothelial cell tissue factor procoagulant activity in vitro
95. Coagulation initiated on herpes-viruses
96. Prothrombinase assembly on an enveloped virus: Evidence that the cytomegalovirus surface contains procoagulant phospholipid
97. Expression of human thrombomodulin cofactor activity in porcine endothelial cells
98. Retroviral vectors for long-term expression of allogeneic major histocompatibility complex transduced into syngeneic bone marrow cells
99. Inhibitory effect of prostacyclin and nitroprusside on type IIb von Willebrand factor-promoted platelet activation
100. Use of von Willebrand diseased kidney as donor in a pig-to-primate model of xenotransplantation